CASI Pharmaceuticals, Inc. 4
4 · CASI Pharmaceuticals, Inc. · Filed Jun 3, 2016
Insider Transaction Report
Form 4
Ren Ken Keyong
Chief Executive Officer
Transactions
- Award
Stock Options (Right to Buy)
2016-06-02+280,701→ 280,701 totalExercise: $0.86From: 2016-06-02Exp: 2026-03-11→ Common Stock (280,701 underlying)
Footnotes (1)
- [F1]The option grant was approved by the Board of Directors on March 11, 2016, subject to stockholder approval of amendments to the 2011 Long-Term Incentive Plan (the "Amendments"). The Company's stockholders approved the Amendments on June 2, 2016.